Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 15/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809084 | 0.91 | SMN1; SMN2 (0.66) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL13273862 | 0.86 | MAPT (0.63) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL6809066 | 0.80 | TP53 (0.52) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL6808404 | 0.78 | HAVCR2 (0.60) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL6806801 | 0.76 | MAPT (0.62) | TP53NPC1LMNAMAPK1RAB9A | |
| SCHEMBL6989364 | 0.75 | TP53 (0.51) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL6989368 | 0.74 | TP53 (0.46) | HAVCR2TP53NPC1LMNAGAA | |
| SCHEMBL6809002 | 0.74 | F10 (0.60) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6808723 | 0.72 | SMN1; SMN2 (0.60) | TP53NPC1MAPK1HTTRAB9A | |
| SCHEMBL8268112 | 0.72 | MAPT (0.60) | HAVCR2TP53NPC1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | HAVCR2 226/4885TP53 1748/4885NPC1 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.